Enosium Life Science takes a major step toward becoming the European leader in scientific services for the healthcare industries with three strategic acquisitions:
- Inbeeo: a leading consultancy specialized in market access and pricing strategies for medicines and medical devices in Europe
- Vyoo Agency: one of the few firms highly specialized in health economics and outcomes research (HEOR)
- Epione: a major player in the French medical and scientific communications market, known for its brands KPL, ALINEA PLUS, and SIRIUS
Three specialized acquisitions
With these acquisitions in France and the UK, Enosium Life Science strengthens its position as a unique European platform offering tailor-made and innovative solutions for pharmaceutical, biotech, and Medtech companies.
A pan-European presence from the start
Inbeeo and Vyoo Agency support pharma and Medtech companies with customized strategies and solutions that facilitate market access and optimize the value of innovative medicines in a highly complex European environment, where pricing, access, and commercialization remain challenging.
The French group Epione and its three entities—KPL, a French leader in medical affairs; Alinea Plus, dedicated to scientific events and congresses; and Sirius Customizer, focused on strategic consulting and patient pathways—bring deep expertise in medical communications, combining scientific rigor with creativity.
Together, these acquisitions bring Enosium Life Science to nearly €15 million in consolidated revenue and a team of 70 employees, reaffirming its ambition to build a multi-specialist group active across the entire healthcare value chain, from clinical development to commercialization.
Enosium Life Science intends to continue its external growth strategy in the coming months, while working on integration and synergies across its entities. These synergies will enable the group to deliver unique, high-value advisory services, supporting clients in the successful launch of their innovations across Europe.
Antoine Amer, Founder and CEO of Enosium Life Science, said:
“I am proud to welcome Hervé Lilliu, Founder of Inbeeo; Stéphane Roze, Founder of Vyoo Agency; and Catherine Auzimour and Pierre-Louis Prost, co-founders of the Epione group, along with their 65 talented and recognized experts in France and internationally. Our ambition is to quickly become the partner of choice for pharma, biotech, and Medtech companies, by offering highly specialized scientific advisory services across Europe and the entire healthcare value chain. We aim to become a European leader by continuing our external growth strategy while creating strong synergies between our entities. Our mission is to help clients succeed in launching their innovations in France and Europe, enabling faster and broader patient access to high-quality medical innovations.”
Hervé Lilliu, President and Founder of Inbeeo, said:
“We are very pleased to join Enosium Life Science, with whom we share a common vision: accelerating access to innovation for all. Being part of a new integrated group unique in Europe allows us to offer cutting-edge scientific services and strategic consulting to the healthcare industries.”
Stéphane Roze, President and Founder of Vyoo Agency, added:
“Joining Enosium Life Science will give us access to broader markets and allow us to create strong synergies with other expertise areas that our clients increasingly need.”
Catherine Auzimour and Pierre-Louis Prost, co-founders of the Epione group (KPL, Sirius Customizer, Alinea Plus), concluded:
“We are delighted to join Enosium and contribute to building a new group with strong capabilities across the full healthcare value chain. We share the same commitments to our clients: personalized service, scientific rigor, and client satisfaction. The synergies created will enhance Epione’s offerings and help us address the key challenges of pharmaceutical companies, positioning us as a European leader in medical affairs.”
Basile Paul-Petit, Partner at Alpera Partners, said:
“We strongly believe in Enosium’s value potential and in its strategy of integrating high-quality scientific services into Europe’s healthcare ecosystem. These acquisitions confirm this vision and position Enosium as a leading player ready to redefine healthcare services with innovative solutions.”
About Enosium Life Science
Founded in 2024 by Dr. Antoine Amer with the financial backing of Alpera Partners, Enosium Life Science is an integrated scientific services group covering clinical research, regulatory affairs, market access and health economics, medical affairs, marketing, and public affairs for the healthcare industries in Europe. Its mission is to bring together the best expertise across Europe to provide a unique and comprehensive range of scientific services, supporting innovation and excellence in life sciences and ensuring faster, broader patient access to medical innovations.
About Alpera Partners
Working alongside bold entrepreneurs, Alpera Partners creates, develops, and scales the leading groups of tomorrow through roll-up platforms.
Each year, Alpera Partners invests more than €80 million in equity to consolidate micro-cap companies in fragmented, high-growth markets and support their growth both organically and through acquisitions. Its focus sectors include healthcare, industry, business services, and real estate.
As of August 2024, Alpera Partners has launched four roll-up platforms in hospitality (Otelium), nuclear (Alfeor), healthcare (Enosium Life Science), and vertical software (Comet Software). These complement its established platform in veterinary healthcare (Novavet).
.png)